Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284847 | 1.00 | CA2 (0.41) | CA2CA9CA1CA12CA7 | |
| SCHEMBL17542206 | 0.86 | CA2 (0.42) | CA2CA9CA1CA12CA7 | |
| SCHEMBL17542204 | 0.86 | CA2 (0.42) | CA2CA9CA1CA12CA7 | |
| SCHEMBL17542369 | 0.86 | CA2 (0.42) | CA2CA9CA1CA12CA7 | |
| SCHEMBL276258 | 0.82 | CA2 (0.50) | CA2CA9CA1CA12CA7 | |
| SCHEMBL23670999 | 0.80 | CA2 (0.41) | CA2CA9 | |
| SCHEMBL19285314 | 0.80 | CA2 (0.41) | CA2CA9 | |
| SCHEMBL19285491 | 0.80 | CA2 (0.41) | CA2CA9 | |
| SCHEMBL19285427 | 0.79 | CA2 (0.46) | CA2CA9CA1 | |
| SCHEMBL23668895 | 0.79 | CA2 (0.46) | CA2CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CA2 4708/4885CA9 4746/4885CA1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.